Praxis Precision Medicines (PRAX)
Praxis Precision Medicines on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.2M
Short interest
settlement 2026-09-30
7.2
Days to cover
-7.7 days vs prior
24.2%
Short share of volume
2026-10-09
760
Fails to deliver
settlement 2026-09-14
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in PRAX is 4,188,193 shares, up 447,442 shares over the last month. Over the last 48 readings it ranged from 1,465,295 shares (29 November 2024) to 4,188,193 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 585K shares a day that is 7.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/prax" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 4,188,193 | +10.3% | 585,284 | 7.16 |
| 2026-09-15 | 3,795,697 | +1.5% | 255,094 | 14.88 |
| 2026-08-31 | 3,740,751 | +0.7% | 368,146 | 10.16 |
| 2026-08-14 | 3,714,692 | +1.6% | 476,576 | 7.79 |
| 2026-07-31 | 3,656,485 | -2.8% | 322,416 | 11.34 |
| 2026-07-15 | 3,763,401 | -5.6% | 408,462 | 9.21 |
| 2026-06-30 | 3,987,219 | +11.7% | 773,350 | 5.16 |
| 2026-06-15 | 3,568,196 | -2.3% | 649,949 | 5.49 |
| 2026-05-29 | 3,651,741 | -1.5% | 302,516 | 12.07 |
| 2026-05-15 | 3,708,318 | -1.8% | 402,661 | 9.21 |
| 2026-04-30 | 3,775,673 | -0.1% | 403,874 | 9.35 |
| 2026-04-15 | 3,779,307 | -4.4% | 366,749 | 10.30 |
| 2026-03-31 | 3,953,698 | +5.6% | 476,470 | 8.30 |
| 2026-03-13 | 3,743,162 | -1.1% | 378,064 | 9.90 |
| 2026-02-27 | 3,786,207 | -0.2% | 393,593 | 9.62 |
| 2026-02-13 | 3,795,192 | -1.7% | 457,492 | 8.30 |
| 2026-01-30 | 3,859,164 | +3.0% | 569,952 | 6.77 |
| 2026-01-15 | 3,747,796 | -0.3% | 611,234 | 6.13 |
| 2025-12-31 | 3,760,427 | +2.4% | 615,494 | 6.11 |
| 2025-12-15 | 3,672,170 | +3.4% | 1,064,853 | 3.45 |
| 2025-11-28 | 3,550,804 | -1.7% | 1,166,693 | 3.04 |
| 2025-11-14 | 3,613,141 | +18.1% | 759,798 | 4.76 |
| 2025-10-31 | 3,058,291 | +17.1% | 2,205,974 | 1.39 |
| 2025-10-15 | 2,611,630 | -1.0% | 315,432 | 8.28 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of PRAX volume is 24.2%, down 53.1 points over the last five sessions. Over the last 30 readings it ranged from 24.2% (9 October 2026) to 82.7% (22 September 2026). The latest reading sits at the bottom of that range. The latest reading is 36.8 points below the 30-session average of 61.0%, on 213K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 52K | 213K | 24.2% | 0 |
| 2026-10-08 | 98K | 359K | 27.2% | 0 |
| 2026-10-07 | 112K | 204K | 55.1% | 0 |
| 2026-10-06 | 102K | 157K | 65.2% | 0 |
| 2026-10-05 | 126K | 209K | 60.3% | 0 |
| 2026-10-02 | 147K | 191K | 77.2% | 0 |
| 2026-10-01 | 112K | 172K | 64.8% | 0 |
| 2026-09-30 | 177K | 244K | 72.5% | 396 |
| 2026-09-29 | 59K | 108K | 55.2% | 9 |
| 2026-09-28 | 123K | 193K | 63.6% | 0 |
| 2026-09-25 | 125K | 199K | 62.6% | 0 |
| 2026-09-24 | 150K | 251K | 59.5% | 14 |
| 2026-09-23 | 278K | 477K | 58.4% | 0 |
| 2026-09-22 | 227K | 275K | 82.7% | 0 |
| 2026-09-21 | 135K | 268K | 50.3% | 0 |
| 2026-09-18 | 202K | 252K | 80.1% | 0 |
| 2026-09-17 | 197K | 279K | 70.5% | 6 |
| 2026-09-16 | 166K | 250K | 66.4% | 0 |
| 2026-09-15 | 41K | 87K | 47.1% | 0 |
| 2026-09-14 | 93K | 132K | 70.6% | 0 |
| 2026-09-11 | 32K | 63K | 51.4% | 12 |
| 2026-09-10 | 60K | 109K | 55.0% | 0 |
| 2026-09-09 | 89K | 218K | 40.5% | 8 |
| 2026-09-08 | 54K | 121K | 44.4% | 2 |
| 2026-09-04 | 56K | 79K | 70.5% | 0 |
| 2026-09-03 | 50K | 77K | 64.7% | 9 |
| 2026-09-02 | 88K | 134K | 65.9% | 9 |
| 2026-09-01 | 94K | 139K | 67.5% | 54 |
| 2026-08-31 | 99K | 123K | 80.4% | 0 |
| 2026-08-28 | 99K | 129K | 76.4% | 1 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in PRAX is 760 shares, up 323 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (13 August 2026) to 8,350 shares (8 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 760 | $334.58 | $254K |
| 2026-08-27 | 437 | $377.37 | $165K |
| 2026-08-25 | 49 | $368.03 | $18K |
| 2026-08-13 | 3 | $386.33 | $1K |
| 2026-08-12 | 272 | $370.68 | $101K |
| 2026-08-11 | 1,544 | $366.96 | $567K |
| 2026-08-10 | 2,021 | $360.76 | $729K |
| 2026-08-07 | 1,204 | $370.16 | $446K |
| 2026-08-04 | 67 | $305.51 | $20K |
| 2026-08-03 | 67 | $307.83 | $21K |
| 2026-07-08 | 8,350 | $323.95 | $2.7M |
| 2026-07-06 | 568 | $318.52 | $181K |
| 2026-06-30 | 62 | $350.56 | $22K |
| 2026-06-29 | 203 | $327.79 | $67K |
| 2026-06-25 | 300 | $308.94 | $93K |
| 2026-06-23 | 230 | $303.39 | $70K |
| 2026-06-22 | 21 | $282.31 | $6K |
| 2026-06-18 | 166 | $270.01 | $45K |
| 2026-06-15 | 143 | $266.58 | $38K |
| 2026-06-11 | 23 | $240.66 | $6K |
| 2026-06-02 | 8 | $335.16 | $3K |
| 2026-05-22 | 158 | $350.56 | $55K |
| 2026-05-18 | 2,579 | $342.58 | $884K |
| 2026-05-14 | 458 | $346.84 | $159K |
| 2026-05-05 | 100 | $337.61 | $34K |
| 2026-04-21 | 1,203 | $342.57 | $412K |
| 2026-03-25 | 806 | $294.65 | $237K |
| 2026-03-04 | 10 | $318.22 | $3K |
| 2026-02-27 | 4,606 | $340.47 | $1.6M |
| 2026-02-23 | 1,310 | $335.28 | $439K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for PRAX in the last 90 days. The most recent filings are listed below. Latest filing: Souza Marcio (Chief Executive Officer) on 2026-07-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-08 | Souza Marcio | Chief Executive Officer | Gift | 3K | $0.00 | $0 | 0 |
| 2026-07-08 | Souza Marcio | Chief Executive Officer | Gift | 21K | $0.00 | $0 | 56K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 120 | $303.13 | $36K | 14K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 320 | $305.31 | $98K | 13K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 683 | $306.77 | $210K | 13K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 1K | $308.24 | $382K | 12K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 999 | $309.38 | $309K | 11K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 2K | $310.89 | $544K | 9K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 3K | $311.91 | $890K | 6K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 1K | $312.83 | $314K | 5K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 504 | $313.66 | $158K | 4K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 837 | $315.71 | $264K | 2K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 1K | $314.90 | $403K | 3K |
| 2026-06-24 | DeSimone Jill | Director | Option exercise | 9K | $44.25 | $379K | 11K |
| 2026-06-24 | DeSimone Jill | Director | Option exercise | 3K | $147.30 | $447K | 14K |
| 2026-06-24 | DeSimone Jill | Director | Sell | 10 | $301.44 | $3K | 14K |
| 2026-06-10 | Norden Gregory | Director | Grant | 1K | $0.00 | $0 | 2K |
| 2026-06-10 | KINDLER JEFFREY B | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2026-06-10 | MITCHELL DEAN J | Director | Grant | 1K | $0.00 | $0 | 19K |
| 2026-06-10 | Cudkowicz Merit Ester | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2026-06-10 | DeSimone Jill | Director | Grant | 1K | $0.00 | $0 | 2K |
| 2026-06-10 | YOUNG WILLIAM D | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2026-06-10 | Chodakewitz Jeffrey | Director | Grant | 1K | $0.00 | $0 | 1K |
| 2026-06-10 | Arbuckle Stuart A | Director | Grant | 1K | $0.00 | $0 | 3K |
| 2026-05-14 | Sniecinski Megan | Chief Operating Officer | Grant | 89 | $167.94 | $15K | 29K |
| 2026-05-14 | Souza Marcio | Chief Executive Officer | Grant | 126 | $167.94 | $21K | 77K |
| 2026-05-14 | Nemiroff Alex | General Counsel and Secretary | Grant | 78 | $167.94 | $13K | 26K |
| 2026-05-14 | Mastrocola Lauren | Principal Accounting Officer | Grant | 127 | $167.94 | $21K | 14K |
| 2026-05-14 | Kelly Timothy Edwin | Chief Financial Officer | Grant | 121 | $167.94 | $20K | 31K |
| 2026-02-06 | KINDLER JEFFREY B | Director | Grant | 478 | $0.00 | $0 | 1K |
| 2026-02-06 | KINDLER JEFFREY B | Director | Grant | 688 | $0.00 | $0 | 688 |
| 2026-02-06 | Arbuckle Stuart A | Director | Grant | 478 | $0.00 | $0 | 1K |
| 2026-02-06 | Arbuckle Stuart A | Director | Grant | 688 | $0.00 | $0 | 688 |
| 2026-01-12 | Sniecinski Megan | Chief Operating Officer | Tax withholding | 885 | $275.74 | $244K | 29K |
| 2026-01-12 | Nemiroff Alex | General Counsel and Secretary | Tax withholding | 768 | $275.74 | $212K | 26K |
| 2026-01-12 | Mastrocola Lauren | Principal Accounting Officer | Tax withholding | 344 | $275.74 | $95K | 13K |
| 2026-01-12 | Kelly Timothy Edwin | Chief Financial Officer | Tax withholding | 943 | $275.74 | $260K | 31K |
| 2026-01-10 | Sniecinski Megan | Chief Operating Officer | Tax withholding | 1K | $288.45 | $314K | 29K |
| 2026-01-10 | Souza Marcio | Chief Executive Officer | Tax withholding | 4K | $288.45 | $1.2M | 77K |
| 2026-01-10 | Nemiroff Alex | General Counsel and Secretary | Tax withholding | 917 | $288.45 | $265K | 27K |
| 2026-01-10 | Mastrocola Lauren | Principal Accounting Officer | Tax withholding | 367 | $288.45 | $106K | 14K |
| 2026-01-10 | Kelly Timothy Edwin | Chief Financial Officer | Tax withholding | 1K | $288.45 | $385K | 32K |
| 2026-01-08 | Sniecinski Megan | Chief Operating Officer | Grant | 10K | $0.00 | $0 | 31K |
| 2026-01-08 | Souza Marcio | Chief Executive Officer | Grant | 28K | $0.00 | $0 | 81K |
| 2026-01-08 | Nemiroff Alex | General Counsel and Secretary | Grant | 7K | $0.00 | $0 | 28K |
| 2026-01-08 | Mastrocola Lauren | Principal Accounting Officer | Grant | 4K | $0.00 | $0 | 14K |
| 2026-01-08 | Kelly Timothy Edwin | Chief Financial Officer | Grant | 9K | $0.00 | $0 | 33K |
| 2026-01-07 | Souza Marcio | Chief Executive Officer | Tax withholding | 405 | $292.63 | $119K | 54K |
| 2026-01-07 | Nemiroff Alex | General Counsel and Secretary | Tax withholding | 89 | $292.63 | $26K | 21K |
| 2026-01-07 | Mastrocola Lauren | Principal Accounting Officer | Tax withholding | 35 | $292.63 | $10K | 10K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON3 Form 144 notices on file for PRAX worth $11.1M at the prices reported; 0 in the last 90 days worth $0. Latest: DeSimone Jill filed on 2026-06-24 to sell 11,600 shares ($3.6M) from 2026-06-24.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-24 | DeSimone JillDirector | 12K | $3.6M | 0.042% | 2026-06-24 | Fidelity Brokerage Services LLC |
| 2025-11-20 | Nemiroff AlexOfficer | 25K | $4.9M | 0.100% | 2025-11-20 | Fidelity Brokerage Services LLC |
| 2025-11-20 | Mastrocola LaurenOfficer | 14K | $2.6M | 0.054% | 2025-11-20 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON13 holders report 5% or more of PRAX in their latest filing, all on Schedule 13G (passive). The largest reported stake is JANUS HENDERSON GROUP PLC at 12.3% of the class (2,763,859 shares), filed 2025-11-14 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 2 | ORBIS INVESTMENT MANAGEMENT LTDnon-US institution | 1.5M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Allan Gray Australia Pty Ltdnon-US institution | 3K | 0.0% | 2026-06-30 |
| 2026-05-15 | 13G | Julian C. Bakerparent holding company, individual | 1.8M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 1.8M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G | Baker Bros. Advisors LPinvestment adviser, partnership | 1.8M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G | Felix J. Bakerparent holding company, individual | 1.8M | 6.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Steven A. Cohenindividual | 66K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Differentiated Ventures Investments, LLCother entity | 66K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | 72 Investment Holdings, LLCother entity | 66K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Point72 Biotech Private Investments, LLCother entity | 66K | 0.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Point72 Capital Advisors, Inc.corporation | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 8 | Point72 Asset Management, L.P.partnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 2.2M | 7.7% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | FMR LLCparent holding company | 2.2M | 7.7% | 2026-03-31 |
| 2026-04-30 | 13G | Vanguard Capital Managementinvestment adviser | 1.4M | 5.1% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 2 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 1 | Perceptive Life Sciences Master Fund, Ltd.corporation | 2.0M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Perceptive Advisors LLCinvestment adviser | 2.0M | 7.2% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Joseph Edelmanindividual | 2.0M | 7.2% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 4 | Adage Capital Management, L.P.investment adviser, partnership | 965K | 3.8% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 4 | Robert Atchinsonparent holding company, individual | 965K | 3.8% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 4 | Phillip Grossparent holding company, individual | 965K | 3.8% | 2025-12-31 |
| 2025-11-14 | 13G/Ano. 3 | JANUS HENDERSON GROUP PLCinvestment adviser, parent holding company | 2.8M | 12.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 3 | Janus Henderson Biotech Innovation Master Fund Ltdinvestment company | 1.4M | 6.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Bihua Chenparent holding company, individual | 1.0M | 4.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Cormorant Asset Management, LPinvestment adviser, partnership | 1.0M | 4.0% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | T. Rowe Price Associates, Inc.investment adviser | 1.0M | 4.8% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 1 | Morgan Stanleyparent holding company, corporation | 618K | 2.9% | 2025-09-30 |
| 2025-11-07 | 13G/Ano. 1 | Morgan Stanley Capital Services LLCbroker-dealer, corporation | 297K | 1.4% | 2025-09-30 |
13F holders
Tracked managers holding PRAX at their latest 13F. JSON5 of the 30 tracked managers held PRAX at their latest 13F, $30.4M in total at quarter-end prices. AQR Capital Management is the largest at $19.6M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 58K | $19.6M | 0.01% | -210 |
| Two Sigma Investments | 2026-06-30 | 19K | $6.3M | 0.00% | +1K |
| Citadel Advisors | 2026-06-30 | 7K | $2.5M | 0.00% | new |
| D. E. Shaw & Co. | 2026-06-30 | 5K | $1.7M | 0.00% | new |
| Millennium Management | 2026-06-30 | 995 | $333K | 0.00% | -3K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$249.1M of operating cash flow.
- Cash
- $474.8M
- Equity
- $1.34B
- Total assets
- $1.39B
- Shares outstanding
- 27,919,988
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$83.7M | n/a | -2.87 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$92.6M | n/a | -3.20 |
| Q4 FY 2025derived | 2025-12-31 | $0 | -$88.9M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $0 | -$73.9M | n/a | -3.36 |
| Q2 FY 2025 | 2025-06-30 | $0 | -$71.1M | n/a | -3.31 |
| Q1 FY 2025 | 2025-03-31 | $0 | -$69.3M | n/a | -3.29 |
| Q4 FY 2024 | 2024-12-31 | n/a | -$58.7M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $302K | -$51.9M | -17188.7% | -2.75 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | -$303.3M | -$249.1M | $56K | n/a | n/a |
| FY 2024 | 2024-12-31 | $8.6M | -$182.8M | -$131.8M | $0 | n/a | n/a |
| FY 2023 | 2023-12-31 | $2.4M | -$123.3M | -$111.1M | $50K | n/a | n/a |
| FY 2022 | 2022-12-31 | $0 | -$214.0M | -$185.0M | $444K | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$167.1M | -$124.6M | $1.1M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Praxis Precision Medicines in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Praxis Precision Medicines (PRAX), SEC CIK 1689548, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-24.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1689548Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of PRAX is sold short?
What is PRAX's daily short volume?
Does PRAX have fails to deliver?
Are PRAX insiders buying or selling?
Have PRAX insiders filed to sell?
Who owns 5% or more of PRAX?
What did PRAX report last quarter?
Which tracked 13F managers own PRAX?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.